×
ResMed Receivables 2010-2024 | RMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ResMed receivables for the quarter ending September 30, 2024 were
$0.811B
, a
17.16% increase
year-over-year.
ResMed receivables for 2024 were
$0.837B
, a
18.78% increase
from 2023.
ResMed receivables for 2023 were
$0.705B
, a
22.39% increase
from 2022.
ResMed receivables for 2022 were
$0.576B
, a
6.24% decline
from 2021.
View More
ResMed Receivables 2010-2024 | RMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ResMed receivables for 2024 were
$0.837B
, a
18.78% increase
from 2023.
ResMed receivables for 2023 were
$0.705B
, a
22.39% increase
from 2022.
ResMed receivables for 2022 were
$0.576B
, a
6.24% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$202.2B
Stryker (SYK)
$143.3B
Boston Scientific (BSX)
$130.1B
Medtronic (MDT)
$112.5B
EssilorLuxottica (ESLOY)
$111.7B
Lonza Group Ag (LZAGY)
$45.4B
Haleon (HLN)
$43.5B
GE HealthCare Technologies (GEHC)
$39.3B
Terumo (TRUMY)
$29.6B
Koninklijke Philips (PHG)
$25B
Zimmer Biomet Holdings (ZBH)
$21.5B
Insulet (PODD)
$18.8B
Baxter (BAX)
$17.7B
Smith & Nephew SNATS (SNN)
$10.6B
Bio-Rad Laboratories (BIO)
$10.3B
BellRing Brands (BRBR)
$9.1B
Demant (WILYY)
$8.4B
Lantheus Holdings (LNTH)
$6.1B
Haemonetics (HAE)
$4.5B
TG Therapeutics (TGTX)
$4.5B
ICU Medical (ICUI)
$4.3B
Prestige Consumer Healthcare (PBH)
$4B
Perrigo (PRGO)
$3.6B
Neogen (NEOG)
$3.5B
Envista Holdings (NVST)
$3.5B
Agios Pharmaceuticals (AGIO)
$3.4B
GN Store Nord (GNNDY)
$3B
Shandong Weigao Medical Polymer (SHWGF)
$3B
QuidelOrtho (QDEL)
$2.9B
LeMaitre Vascular (LMAT)
$2.3B